首页|编码基因/非编码基因调控CD44在多种肿瘤耐药机制中的研究进展

编码基因/非编码基因调控CD44在多种肿瘤耐药机制中的研究进展

扫码查看
多种肿瘤(胰腺癌,肺癌,结直肠癌等)长效耐药细胞显著增强其转移性,且诱导CD44蛋白表达。CD44是一种非激酶受体,在多种肿瘤中作为肿瘤干细胞标记物在侵袭和转移中发挥重要作用。早期联合一线化疗药和靶向CD44的药物、探索靶向CD44的合理给药时间点可能提升临床已转移的恶性肿瘤患者的总体生存率。从编码基因(转录因子、异质核糖核蛋白、上皮剪接调节蛋白、细胞因子以及蛋白激酶)和非编码基因(LncRNA、miRNA和circRNA)两方面介绍CD44上游调控因子介导的肿瘤耐药和转移机制。此外,还总结在耐药肿瘤细胞中CD44的亚型转换、表达调控、CD44下游效应分子的信号通路和CD44作为癌症治疗靶点的临床意义。
Research progress of mechanisms in CD44 mediated chemoresistance by coding/Non-coding genes in various tumors
Long term drug-resistant cells significantly enhance tumor metastasis and induce CD44 protein expression in multiple cancer types(pancreatic cancer,lung cancer,colorectal cancer,etc.).CD44 is a non-kinase receptor that plays an important role as a tumor stem cell marker in invasion and metastasis of various tumors.A combination of first-line chemotherapeutic drugs and CD44-targeted drugs at an early administration time point may improve the overall survival rate of advanced metastasis of cancer patients.This review summarized the mechanisms of tumor resistance and metastasis mediated by CD44 protein from its upstream regulators such as coding genes(transcription factors,hetero-ribonucleoproteins,epithelial splicing regulatory pro-teins,cytokines,and protein kinases)and non-coding genes(lncRNA,miRNA,and circRNA).In addition,CD44 isoform switch,CD44 gene regulation,CD44 downstream signaling pathways mediated cancer cells drug-resistance,and the clinical sig-nificance of CD44 as a cancer therapeutic target were also summarized.

CD44drug resistancecancerlong non coding RNAgene regulation

陈琛、高亮、孙依鹏、陈敬华

展开 >

江南大学生命科学与健康工程学院,江苏无锡 214122

CD44 耐药 癌症 非编码RNA 基因调控

江苏省品牌专业建设工程二期项目中国博士后科研基金中国科协2019年度中外优秀青年交流项目(CAST)

2020M681492

2024

西南民族大学学报(自然科学版)
西南民族大学

西南民族大学学报(自然科学版)

CSTPCD
影响因子:0.441
ISSN:2095-4271
年,卷(期):2024.50(5)